Literature DB >> 21874011

Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney.

Guido Martignoni1, Franco Bonetti, Marco Chilosi, Matteo Brunelli, Diego Segala, Mahul B Amin, Pedram Argani, John N Eble, Stefano Gobbo, Maurizio Pea.   

Abstract

The perivascular epithelioid cell (PEC) is a unique cell type coexpressing contractile proteins (mainly α-smooth muscle actin), melanocytic markers, including microphthalmia-associated transcription factor (MITF), and estrogen and progesterone receptors. It is constantly present in a group of tumors called PEComas. Renal PEComas include the common angiomyolipoma as well as less common lesions such as microscopic angiomyolipoma, intraglomerular lesions, angiomyolipoma with epithelial cysts, epithelioid angiomyolipoma, oncocytoma-like angiomyolipoma and lymphangioleiomyomatosis of the renal sinus. It has been demonstrated that most of these lesions are determined by mutations affecting genes of the tuberous sclerosis complex, tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2), with eventual deregulation of the RHEB/MTOR/RPS6KB2 pathway, and it has been observed that some PEComas regressed during sirolimus therapy, an MTOR inhibitor. Recently, overexpression of MITF has been related to the expression of the papain-like cysteine protease cathepsin K in osteoclasts where it has inhibited MTOR. The aim of this study is to evaluate cathepsin K immunohistochemically in the entire spectrum of PEComa lesions in the kidney. The study population consisted of 84 renal PEComa lesions, including 5 composed predominantly of fat (lipoma-like angiomyolipoma), 15 almost exclusively composed of spindle-shaped smooth muscle cells (leiomyoma-like angiomyolipoma) and 31 common angiomyolipomas composed of a mixture of fat, spindle and epithelioid smooth muscle cells, and abnormal thick-walled blood vessels, 15 microscopic angiomyolipomas, 5 intraglomerular lesions, 2 oncocytoma-like angiomyolipomas, 8 epithelioid angiomyolipomas, 2 angiomyolipomas with epithelial cysts and 1 example of lymphangioleiomyomatosis of the renal sinus. In all of the renal PEComas, cathepsin K was found to be constantly and strongly expressed and seems to be a more powerful marker than other commonly used markers for their identification, especially to confirm the diagnosis on needle biopsies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874011     DOI: 10.1038/modpathol.2011.136

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  22 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

Review 2.  Perivascular epithelioid tumours (PEComas) of the gynaecological tract.

Authors:  Niamh Conlon; Robert A Soslow; Rajmohan Murali
Journal:  J Clin Pathol       Date:  2015-03-06       Impact factor: 3.411

3.  "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.

Authors:  Huiying He; Kiril Trpkov; Petr Martinek; Ozlem Tanas Isikci; Cristina Maggi-Galuzzi; Reza Alaghehbandan; Anthony J Gill; Maria Tretiakova; Jose Ignacio Lopez; Sean R Williamson; Delia Perez Montiel; Maris Sperga; Eva Comperat; Fadi Brimo; Ali Yilmaz; Kristyna Pivovarcikova; Kveta Michalova; David Slouka; Kristyna Prochazkova; Milan Hora; Michael Bonert; Michal Michal; Ondrej Hes
Journal:  Virchows Arch       Date:  2018-09-19       Impact factor: 4.064

4.  Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung.

Authors:  Anna Caliò; Maria Cecilia Mengoli; Alberto Cavazza; Giulio Rossi; Claudio Ghimenton; Matteo Brunelli; Maurizio Pea; Marco Chilosi; Lisa Marcolini; Guido Martignoni
Journal:  Virchows Arch       Date:  2018-03-07       Impact factor: 4.064

5.  Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity.

Authors:  Sean R Williamson; Liang Cheng; John N Eble; Lawrence D True; Nilesh S Gupta; Mingsheng Wang; Shaobo Zhang; David J Grignon
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

6.  Perivascular epithelioid cell tumor (PEComa) with TFE3 gene rearrangement: clinicopathological, immunohistochemical, and molecular features.

Authors:  Qin Shen; Qiu Rao; Qiu-Yuan Xia; Bo Yu; Qun-Li Shi; Ru-Song Zhang; Xiao-Jun Zhou
Journal:  Virchows Arch       Date:  2014-09-20       Impact factor: 4.064

7.  Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction.

Authors:  Izabela Malinowska; David J Kwiatkowski; Sharon Weiss; Guido Martignoni; George Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

8.  Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features.

Authors:  Qiu Rao; Xiu-Mei Zhang; Pin Tu; Qiu-Yuan Xia; Qin Shen; Xiao-Jun Zhou; Qun-Li Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

9.  Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.

Authors:  Doreen N Palsgrove; Yunjie Li; Christine A Pratilas; Ming-Tseh Lin; Aparna Pallavajjalla; Christopher Gocke; Angelo M De Marzo; Andres Matoso; George J Netto; Jonathan I Epstein; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2018-09       Impact factor: 6.394

10.  A broad survey of cathepsin K immunoreactivity in human neoplasms.

Authors:  Gang Zheng; Guido Martignoni; Cristina Antonescu; Elizabeth Montgomery; Charles Eberhart; George Netto; Janis Taube; William Westra; Jonathan I Epstein; Tamara Lotan; Anirban Maitra; Edward Gabrielson; Michael Torbenson; Christine Iacobuzio-Donahue; Angelo Demarzo; Ie Ming Shih; Peter Illei; T C Wu; Pedram Argani
Journal:  Am J Clin Pathol       Date:  2013-02       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.